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Abstract: Brazil is one of the world’s largest economies and pharmaceutical markets, having the Brazilian government 
as an important purchaser. There are strong local companies that have grown sustainably after the introduction of ge-
nerics and are investing in both incremental and radical innovation. However, research and development (R&D) ex-
penditures are still modest; this could be explained by a combination of economic and political uncertainty in the past 
few years and a bureaucratic, complex regulatory framework. New regulations, efforts to reduce ethical and regulatory 
review timelines, and a Senate bill aimed to accomplish that goal should constitute the definitive regulatory landmark 
for boosting clinical research. In addition to government investments they have given a breath of relief in the market, as 
Brazil is trying to, once again, gain momentum as a “must-go” country for clinical development. Non-profit associa-
tions such as the Brazilian Society of Pharmaceutical Medicine (Sociedade Brasileira de Medicina Farmacêuti-
ca-SBMF), the Brazilian Association of CROs (Associação Brasileira de Organizações Representativas de Pesquisa 
Clínica-ABRACRO), the Brazilian Clinical Research Alliance (Aliança Pesquisa Clínica Brasil), amongst others, 
helped to give the impulse to trigger such changes. It is time to invest heavily in developing educational programs to 
address the growing need for clinical development scientists and physicians. 
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1. Introduction 
1.1 Brazilian Pharmaceutical Market and R&D 
ith a population of 206.1 million people 
and a total gross domestic product (GDP) 
of US$ 2.417 trillion, Brazil figures as one 
of the top 10 world’s economies
[1]
. The pharmaceuti-
cal sector in Brazil is an important business; by 2020, 
the pharmaceutical market should increase at a rate 
of 7% to 10% annually, reaching the sum of BRL 
107 billion. The institutional public market represents  
almost 23% of the total value
[2]
. Data on R&D invest- 
ments in Brazil are limited; in 2009, local affiliates of 
global companies have received only US$ 140 million 
of the US$ 40 billion invested globally
[3]
.  
2. Regulatory and Ethical Framework for 
Clinical Trials in Brazil 
2.1 The First Years 
Historically, the approval process for clinical trials in 
Brazil has been complex, slow, and bureaucratic. The  
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first ethical landmark is the National Health Council 
(Conselho Nacional de Saúde-CNS) Resolution 196/96, 
under the guidance of the Helsinki Declaration. The 
ethical review system was established; institutional 
ethics committees were created all over the country 
under the supervision of a Central body, CONEP (Na-
tional Ethics Commission, Comissão Nacional de 
Ética em Pesquisa), with the main purpose of regulat-
ing the system. CONEP should also deliberate over 
projects with foreign cooperation; by the time, in a 
newly created system and a country on the verge of 
globalization, the idea was to control and avoid “ex-
ploitation” of the studied participants in trials from 
multinational companies. ANVISA, the National Hea-
lth Surveillance Agency (Agência Nacional de Vigil-
ância Sanitária) was created in 1999 and clinical trials 
started being evaluated by the agency. Trial initiation 
should only start after receiving both ethical and reg-
ulatory approvals. A formal appraisal system com-
bined with a large pool of treatment-naïve patients, 
well-trained investigators, and strong academic re-
search sites caught the attention of global pharmaceu-
tical companies that made Brazil a destination for their 
clinical trials, especially on late phases. Over the years, 
the growing number of trials was not accompanied by 
changes in regulations and improved infrastructure of 
CONEP and ANVISA. In the first quarter of 2014, the 
average timeline for ANVISA’s first review was 
around 200 days (Figure 1), with final approval ob-
tained over a year, and on CONEP’s side, first ap-
praisal was received in approximately 180 days with 
total approval timelines reaching 250 days, on the 
same period (Figure 2). Considering that the process 
was sequential (coordinating EC appraisal/approval 
followed by CONEP’s approval and further submis-
sion to ANVISA), we could expect a process of more 
than a year from submission to first-patient-in.  
The lengthy and unpredictable review/approval tim-
elines had a negative impact on the number of clinical 
trials. The new CNS Resolution 466/2012 and Plata-
forma Brasil were issued as a promise to expedite 
CONEP s´ timelines and clarify CONEP’s positioning 
on ethical requirements. Little changed from Resolu-
tion 196/96; data reported by ABRACRO members 
show a decrease in the number of clinical trials sub-
mitted for both ethical and regulatory approvals, from 
80 in 2013 to 59 in 2015. The Brazilian participation 
to global clinical trials over the years remains around 
2%
[4]
. A number of studies were closed prior to initiate 
recruitment. The lack of official metrics made it diffi-
cult to evaluate the impact on the loss of financial in-
vestments, as well as the number of patients that could 
potentially have participated in those trials. 
Different associations started a movement to push 
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Figure 1. ANVISA appraisal and approval timelines as informed by ABRACRO member companies (internal survey). Time for CRO 
response to requirements was not included in the time to final approval.  
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Figure 2. CONEP appraisal and approval timelines as informed by ABRACRO member companies (internal survey). Time for CRO 
response to requirements was not included in the time to final approval. 
 
for a new, more efficient, and competitive scenario for 
clinical trials. Aliança Pesquisa Clínica Brasil was 
created in 2014 and discussions on the matter gained 
strength with the support of senators who embraced 
the idea of creating a definitive regulatory landmark 
for the country. PLS 200/2015 was issued in align-
ment with International Conference on Harmonization 
of Good Clinical Practice (ICH-GCP) guidelines. A lot 
of contributions were made by different players (in-
vestigators, academia, CONEP, ANVISA, and im-
portant Brazilian institutions) and the process is in its 
final stages of analysis at the Senate. Amongst its pos-
itive aspects, the definition of a 30-day period for eth-
ical review and clear provisions for post-trial drug 
access, in alignment with international guidelines, 
were included in the text in order to maintain the 
rights of the participants involved in the studies.  
3. The Current Scenario 
The year 2015 started with a positive initiative from 
ANVISA; the new regulations for clinical trials of 
drugs and medical devices. RDC 09/2015 implement-
ed the Dossier for Drug Clinical Development that 
must contain the entire plan for the drug development, 
as well as the trials that will be conducted in Brazil, 
with thorough details on good manufacturing practice 
(GMP). The definition of a timeline for the first re-
view was defined as 90 days for phase III, internation-
al, multi-centric trials with small molecules. In case of 
no response from ANVISA or absence of further re-
quirements, an importation document is issued and the 
study can be initiated, once all ethical approvals are 
obtained. Phase I and II study protocols, as well as 
those of biological products and products developed 
exclusively in Brazil, have a first review period of up 
to 180 days.  
CONEP has also developed its infrastructure and 
made an effort to reduce the backlog of projects pen-
ding review. Timelines were reduced; in the third 
quarter of 2015, time for first appraisal was reduced to 
approximately 100 days and final CONEP approval 
was obtained in approximately 140 days, as repor-
ted by ABRACRO members.  
4. Educational Efforts 
Over the past 20 years approximately, many courses 
for training clinical research professionals have eme-
rged. In 1999, a Post-Graduation Course on Pharma-
ceutical Medicine was started at the Federal Universi-
ty of São Paulo under the coordination of Dr. João 
Massud Filho. The program of the course was based 
on the syllabus of the Faculty of Pharmaceutical Med-
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icine-London. In 2008, the course was granted accred-
itation by the International Association of Pharmaceu-
tical Physicians (IFAPP). Since 2015, this course is 
given at the Research and Training Institute in Hospi-
tal Sírio-Libanes (Syrian-Lebanese)-São Paulo. 
There is a specific course on Clinical Research given 
at Faculdade de Medicina da Santa Casa de São Paulo 
and other small ongoing courses on clinical trials.  
5. Perspectives  
Biological products, in which, the national industry is 
investing heavily, seem to be the next big step in the 
country s´ clinical research and development. The 
number of clinical trials should increase heavily after 
the bureaucratic issues on regulatory/ethical require-
ments are solved. A growing need for qualified clini-
cal development scientists and physicians is expected, 
and the professional organizations will play a signifi-
cant role in qualifying those professionals in the fol-
lowing years.   
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